32 research outputs found
Raman spectroscopy characterization of 10-cash productions from the late Chinese emperors to the Republic
This is the peer reviewed version of the following article: Montoya, NoemĂ, Montagna, Elena, Lee, Yu, Domenech Carbo, MÂȘ Teresa, DomĂ©nech CarbĂł, Antonio. (2017). Raman spectroscopy characterization of 10-cash productions from the late Chinese emperors to the Republic.Journal of Raman Spectroscopy, 48, 10, 1337-1345. DOI: 10.1002/jrs.5218
, which has been published in final form at http://doi.org/10.1002/jrs.5218. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.[EN] The use of Raman spectroscopy for discriminating monetary emissions, a recurrent problem in much archaeological studies, is described. The method involves the record of Raman signatures of tenorite and crystalline and defective cuprite in the patina based on the idea that subtle, mint-characteristic variations in the composition and metallography of the base metal during the manufacturing process are reflected in the variation in depth of the composition and crystallinity of the corrosion patina. The technique was applied to a series of 10-cash copper coins produced around the transition between the Kuang Hsu and Hsuan Tung last Chinese emperors and the first Republic whose averaged composition was 95 +/- 1% wt Cu plus 5 +/- 1% wt Zn often accompanied by traces of Sn and Pb. Raman data, corroborated by focusing ion beam-field emission scanning electron microscopy and voltammetry of immobilized particles measurements, suggested the possibility of discerning between different provincial and regular unified currency productions.MINECO, Grant/Award Number: CTQ2014-53736-C3-1-P and CTQ2014-53736-C3-2-PMontoya, N.; Montagna, E.; Lee, Y.; Domenech Carbo, MT.; Domenech Carbo, A. (2017). Raman spectroscopy characterization of 10-cash productions from the late Chinese emperors to the Republic. Journal of Raman Spectroscopy. 48(10):1337-1345. https://doi.org/10.1002/jrs.5218S13371345481
Assessing the feasibility, acceptability and accessibility of a peer-delivered intervention to reduce harm and improve the well-being of people who experience homelessness with problem substance use: the SHARPS study
BackgroundFor people experiencing homelessness and problem substance use, access to appropriate services can be challenging. There is evidence that the development of trusting relationships with non-judgemental staff can facilitate service engagement. Peer-delivered approaches show particular promise, but the evidence base is still developing.MethodsThe study used mixed methods to assess the feasibility, acceptability and accessibility of a peer-delivered, relational intervention to reduce harms and improve health/well-being, quality of life and social functioning, for people experiencing homelessness and problem substance use. Four Peer Navigators were employed to support individuals (nâ=â68 total, intervention participants). They were based in outreach services and hostels in Scotland and England. Qualitative interviews were conducted with intervention participants, Peer Navigators and staff in services, and observations were conducted in all settings. Quantitative outcomes relating to participantsâ substance use, physical and mental health, and quality of the Peer Navigator relationship, were measured via a âholistic health checkâ with six questionnaires completed at two time-points.ResultsThe intervention was found to be acceptable to, and feasible and accessible for, participants, Peer Navigators, and service staff. Participants reported improvements to service engagement, and feeling more equipped to access services independently. The lived experience of the Peer Navigators was highlighted as particularly helpful, enabling trusting, authentic, and meaningful relationships to be developed. Some challenges were experienced in relation to the âfitâ of the intervention within some settings. Among participants there were reductions in drug use and risky injecting practices. There were increases in the number of participants receiving opioid substitution therapy. Overall, the intervention was positively received, with collective recognition that the intervention was unique and highly valuable. While most of the measures chosen for the holistic health check were found to be suitable for this population, they should be streamlined to avoid duplication and participant burden.ConclusionsThe study established that a peer-delivered, relational harm reduction intervention is acceptable to, and feasible and accessible for, people experiencing homelessness and problem substance use. While the study was not outcomes-focused, participants did experience a range of positive outcomes. A full randomised controlled trial is now required to assess intervention effectiveness.Trial registrationStudy registered with ISRCTN: 15900054
A large-scale and PCR-referenced vocal audio dataset for COVID-19
The UK COVID-19 Vocal Audio Dataset is designed for the training and
evaluation of machine learning models that classify SARS-CoV-2 infection status
or associated respiratory symptoms using vocal audio. The UK Health Security
Agency recruited voluntary participants through the national Test and Trace
programme and the REACT-1 survey in England from March 2021 to March 2022,
during dominant transmission of the Alpha and Delta SARS-CoV-2 variants and
some Omicron variant sublineages. Audio recordings of volitional coughs,
exhalations, and speech were collected in the 'Speak up to help beat
coronavirus' digital survey alongside demographic, self-reported symptom and
respiratory condition data, and linked to SARS-CoV-2 test results. The UK
COVID-19 Vocal Audio Dataset represents the largest collection of SARS-CoV-2
PCR-referenced audio recordings to date. PCR results were linked to 70,794 of
72,999 participants and 24,155 of 25,776 positive cases. Respiratory symptoms
were reported by 45.62% of participants. This dataset has additional potential
uses for bioacoustics research, with 11.30% participants reporting asthma, and
27.20% with linked influenza PCR test results.Comment: 37 pages, 4 figure
Electrochemical discrimination of mints: The last Chinese emperors Kuang Hsu and Hsuan T'ung monetary unification
[EN] An electrochemical methodology for discriminating monetary emissions, a recurrent problem in much archaeological studies, is introduced. The method is based on the record of voltammetric signatures of cuprite and tenorite corrosion products in the patina using a minimally invasive nanosampling following the voltammetry of immobilized particles methodology. A model for the depth variation of voltammetric electrochemical parameters characterizing the composition of the corrosion patinas is presented. This model permits to rationalize electrochemical data and discriminate different monetary emissions. The application of this technique, corroborated by electrochemical impedance spectroscopy (EIS) and focusing ion beam-field emission scanning electron microscopy (FIB-FESEM-EDX), to a series of 10 cash copper coins produced around the Kuang Hsu and Hsuan Tung last Chinese emperors permits to discern different provincial mints and reveals that the monetary unification developed in this period was not uniform.Financial support from the Spanish MINECO Projects CTQ2014-53736-C3-1-P and CTQ2014-53736-C3-2-P which are also supported with ERDF funds. The Universita degli Studi di roma "La Sapienza" has granted a six-months research-scholarship (d.r.n. 965/2016 prot.n.0022041 del 31/03/2016) to the graduated Elena Montagna. The authors also wish to thank Dr. Jose Luis Moya Lopez and Mr. Manuel Planes Insausti (Microscopy Service of the Universitat Politecnica de Valencia) for technical supportDomenech-Carbo, A.; Domenech Carbo, MT.; Montagna, E.; Ălvarez-Romero, C.; Lee, Y. (2017). Electrochemical discrimination of mints: The last Chinese emperors Kuang Hsu and Hsuan T'ung monetary unification. Talanta. 169:50-56. https://doi.org/10.1016/j.talanta.2017.03.025S505616
A large-scale and PCR-referenced vocal audio dataset for COVID-19
The UK COVID-19 Vocal Audio Dataset is designed for the training and evaluation of machine learning models that classify SARS-CoV-2 infection status or associated respiratory symptoms using vocal audio. The UK Health Security Agency recruited voluntary participants through the national Test and Trace programme and the REACT-1 survey in England from March 2021 to March 2022, during dominant transmission of the Alpha and Delta SARS-CoV-2 variants and some Omicron variant sublineages. Audio recordings of volitional coughs, exhalations, and speech were collected in the âSpeak up and help beat coronavirusâ digital survey alongside demographic, symptom and self-reported respiratory condition data. Digital survey submissions were linked to SARS-CoV-2 test results. The UK COVID-19 Vocal Audio Dataset represents the largest collection of SARS-CoV-2 PCR-referenced audio recordings to date. PCR results were linked to 70,565 of 72,999 participants and 24,105 of 25,706 positive cases. Respiratory symptoms were reported by 45.6% of participants. This dataset has additional potential uses for bioacoustics research, with 11.3% participants self-reporting asthma, and 27.2% with linked influenza PCR test results
Buprenorphine for neuropathic pain in adults
BACKGROUND
Opioid drugs, including buprenorphine, are commonly used to treat neuropathic pain, and are considered effective by some professionals. Most reviews have examined all opioids together. This review sought evidence specifically for buprenorphine, at any dose, and by any route of administration. Other opioids are considered in separate reviews.
OBJECTIVES
To assess the analgesic efficacy of buprenorphine for chronic neuropathic pain in adults, and the adverse events associated with its use in clinical trials.
SEARCH METHODS
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from inception to 11 June 2015, together with reference lists of retrieved papers and reviews, and two online study registries.
SELECTION CRITERIA
We included randomised, double-blind studies of two weeks' duration or longer, comparing any oral dose or formulation of buprenorphine with placebo or another active treatment in chronic neuropathic pain.
DATA COLLECTION AND ANALYSIS
Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality. We did not carry out any pooled analyses.
MAIN RESULTS
Searches identified 10 published studies, and one study with results in ClinicalTrials.gov. None of these 11 studies satisfied our inclusion criteria, and so we included no studies in the review.
AUTHORS' CONCLUSIONS
There was insufficient evidence to support or refute the suggestion that buprenorphine has any efficacy in any neuropathic pain condition
Recommended from our members
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (nâ=â143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (nâ=â152), or no hydrocortisone (nâ=â108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (nâ=â137), shock-dependent (nâ=â146), and no (nâ=â101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707
Finishing the euchromatic sequence of the human genome
The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers âŒ99% of the euchromatic genome and is accurate to an error rate of âŒ1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19
IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.
Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19.
DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 nonâcritically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022).
INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (nâ=â257), ARB (nâ=â248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; nâ=â10), or no RAS inhibitor (control; nâ=â264) for up to 10 days.
MAIN OUTCOMES AND MEASURES The primary outcome was organ supportâfree days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes.
RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ supportâfree days among critically ill patients was 10 (â1 to 16) in the ACE inhibitor group (nâ=â231), 8 (â1 to 17) in the ARB group (nâ=â217), and 12 (0 to 17) in the control group (nâ=â231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ supportâfree days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively).
CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570
Extent of burglary ⊠The 1998 British Crime Survey estimated 1.6
million burglaries against domestic dwellings in England and Wales in 1997. Just under a half of these were attempts in which the offenders failed to gain entry to the home (Section 2)